Banco Bilbao Vizcaya Argentaria S.A. Raises Stake in Boston Scientific Corporation $BSX

Banco Bilbao Vizcaya Argentaria S.A. raised its position in Boston Scientific Corporation (NYSE:BSX) by 194.2% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 104,785 shares of the medical equipment provider’s stock after purchasing an additional 69,174 shares during the period. Banco Bilbao Vizcaya Argentaria S.A.’s holdings in Boston Scientific were worth $10,225,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also modified their holdings of the company. Bridgefront Capital LLC increased its holdings in Boston Scientific by 90.1% in the third quarter. Bridgefront Capital LLC now owns 26,318 shares of the medical equipment provider’s stock valued at $2,569,000 after buying an additional 12,471 shares during the last quarter. Boothbay Fund Management LLC lifted its holdings in Boston Scientific by 1,079.0% during the 3rd quarter. Boothbay Fund Management LLC now owns 28,250 shares of the medical equipment provider’s stock worth $2,758,000 after buying an additional 25,854 shares during the last quarter. Anchor Investment Management LLC lifted its holdings in Boston Scientific by 14.4% during the 3rd quarter. Anchor Investment Management LLC now owns 9,513 shares of the medical equipment provider’s stock worth $929,000 after buying an additional 1,199 shares during the last quarter. Aquatic Capital Management LLC acquired a new position in shares of Boston Scientific during the 3rd quarter worth about $32,325,000. Finally, Arkos Global Advisors increased its holdings in shares of Boston Scientific by 55.5% in the 3rd quarter. Arkos Global Advisors now owns 9,364 shares of the medical equipment provider’s stock valued at $914,000 after acquiring an additional 3,341 shares during the last quarter. 89.07% of the stock is currently owned by institutional investors and hedge funds.

Boston Scientific Stock Up 0.9%

Shares of NYSE BSX opened at $69.15 on Monday. The business has a 50-day moving average price of $82.47 and a 200 day moving average price of $93.21. The stock has a market cap of $102.61 billion, a PE ratio of 35.64, a price-to-earnings-growth ratio of 0.97 and a beta of 0.69. The company has a quick ratio of 1.08, a current ratio of 1.62 and a debt-to-equity ratio of 0.46. Boston Scientific Corporation has a 52-week low of $67.56 and a 52-week high of $109.50.

Boston Scientific (NYSE:BSX) last released its quarterly earnings results on Wednesday, February 4th. The medical equipment provider reported $0.80 EPS for the quarter, topping the consensus estimate of $0.78 by $0.02. Boston Scientific had a return on equity of 19.63% and a net margin of 14.44%.The company had revenue of $5.29 billion for the quarter, compared to analyst estimates of $5.29 billion. During the same quarter in the previous year, the company posted $0.70 earnings per share. The firm’s revenue was up 15.9% compared to the same quarter last year. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. Equities research analysts forecast that Boston Scientific Corporation will post 2.85 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on BSX shares. Barclays cut their target price on Boston Scientific from $136.00 to $124.00 and set an “overweight” rating on the stock in a research report on Tuesday, February 3rd. TD Cowen dropped their price target on shares of Boston Scientific from $115.00 to $100.00 and set a “buy” rating on the stock in a research note on Monday, February 2nd. Evercore cut their price objective on shares of Boston Scientific from $112.00 to $96.00 and set an “outperform” rating on the stock in a report on Thursday, February 5th. Morgan Stanley reduced their price objective on shares of Boston Scientific from $130.00 to $118.00 and set an “overweight” rating for the company in a research report on Thursday, February 5th. Finally, Wells Fargo & Company lowered their target price on shares of Boston Scientific from $125.00 to $94.00 and set an “overweight” rating for the company in a report on Thursday, February 5th. Two research analysts have rated the stock with a Strong Buy rating, twenty have issued a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $108.00.

Insider Activity

In other news, CEO Michael F. Mahoney sold 160,901 shares of Boston Scientific stock in a transaction on Monday, February 2nd. The shares were sold at an average price of $93.49, for a total value of $15,042,634.49. Following the transaction, the chief executive officer directly owned 1,411,735 shares of the company’s stock, valued at $131,983,105.15. The trade was a 10.23% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Company insiders own 0.50% of the company’s stock.

Key Stories Impacting Boston Scientific

Here are the key news stories impacting Boston Scientific this week:

• Neutral Sentiment: Zacks published a recap explaining why Boston Scientific dipped more than the broader market, noting recent volatility around the company. Useful for context on short‑term market reaction. Article Title
• Negative Sentiment: Citigroup lowered its price target for Boston Scientific to $94.00 — a formal analyst downgrade that can weigh on sentiment and may lead some funds to reprice positions. Article Title
• Negative Sentiment: Levi & Korsinsky (reported via PR Newswire) and others say a filed class action alleges Boston Scientific executives misrepresented U.S. electrophysiology procedure volumes — this is the substantive allegation that could lead to discovery, potential damages or settlement risk. Investors should watch pleadings and any company response. Article Title
• Negative Sentiment: Multiple plaintiff law firms (Rosen, Pomerantz, Glancy Prongay Wolke, Robbins Geller, Faruqi, Gross, Bernstein Liebhard, etc.) have issued shareholder alerts and deadline reminders (lead‑plaintiff motions due May 4, 2026). The coordinated outreach increases the likelihood of consolidated litigation and underscores ongoing legal scrutiny. Article Title

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.